ASCO Conference Coverage

ASCO Endorses Integrative Oncology Guidelines For Breast Cancer Patients

(Fred Hutch News Service) June 11, 2018 - The ASCO endorsement, published today in the Journal of Clinical Oncology, came from an expert panel that reviewed a set of clinical practice guidelines for integrative therapies put out by the Society for Integrative Oncology, or SIO.

read article

Researchers Report Findings on Three Biosimilar Trastuzumab Products

(The Center for Biosimilars) June 4, 2018 - During the 2018 American Society of Clinical Oncology's Annual Meeting, researchers presented findings on 3 biosimilar trastuzumab products: Samsung Bioepis’ SB3, Amgen’s ABP 980, and Biocad’s Herticad.

read article

How An Old Diabetes Drug Made A Big Splash At The Biggest Cancer Confab

(Forbes) June 7, 2018 - At the recently concluded annual meeting of the American Society of Clinical Oncology (ASCO) a group of researchers from Mexico City described a surprising discovery: In a phase 2 trial in patients with stage 4 lung cancer, a 24-year-old diabetes drug significantly improved survival when added to a standard therapy.

read article

Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia

(NCI/Cancer Currents Blog) June 5, 2018 - People diagnosed with hairy cell leukemia (HCL), an uncommon form of leukemia, may soon have an effective new treatment option, according to findings from an international phase 3 clinical trial.

read article

Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations

(Pfizer) June 4, 2018 - Pfizer Inc. today announced overall survival (OS) data from the ARCHER 1050 trial evaluating dacomitinib as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations compared to gefitinib.

read corporate press release

AstraZeneca Hails Progress With Key Oncology Drug In Prostate Cancer

(The Telegraph [UK]) June 4, 2018 - One of AstraZeneca’s most important new drugs could help men with advanced prostate cancer, bringing the pharmaceutical company a step closer to its long-term goal of generating $45bn (£33.6bn) of annual sales by 2023.

read article

Doctors Scrutinize Overtreatment, As Cancer Death Rates Decline

(NPR/Shots blog) June 5, 2018 - Are some people getting too much treatment for their cancers? The answer, from the American Society of Clinical Oncology meeting in Chicago, is an emphatic yes.

read article

AZ, MSD’s Lynparza/Abiraterone Combo Hits Prostate Cancer Goals

(PharmaTimes [UK]) June 5, 2018 - AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival in prostate cancer patients taking a combination of Lynparza and abiraterone.

read article

LYNPARZA® (olaparib) in Combination With Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer

(AstraZeneca) June 4, 2018 - AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today presented data, which showed clinical improvement in median radiologic progression-free survival (rPFS) with LYNPARZA® (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a current standard of care, in metastatic castration-resistant prostate cancer (mCRPC). Olaparib is being jointly developed and commercialized by AstraZeneca and Merck.

read corporate press release

ASCO18: Bristol-Myers Fights For Its Place In First-Line Lung Cancer

(BioPharma Dive) June 5, 2018 - Data unveiled Monday from a Phase 3 study found patients with high levels of a biomarker appeared to derive greater benefit from Bristol-Myers Squibb's Opdivo, particularly when paired with the pharma's other immunotherapy Yervoy.

read article

Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

(Daiichi Sankyo) June 4, 2018 - ENLIVEN, the first placebo-controlled study of a systemic investigational therapy in patients with tenosynovial giant cell tumor (TGCT), enrolled patients where surgery would be associated with potentially worsening functional limitation or severe morbidity. Oral pexidartinib significantly reduced tumor size (39 percent overall tumor response rate), compared to no tumor response in patients treated with placebo.

read corporate press release

Verastem Oncology Presents Data on Two Lead Drug Candidates at ASCO 2018 Annual Meeting

(Verastem Oncology) June 4, 2018 - Duvelisib demonstrates robust clinical activity with 73% ORR and a median of 15 month PFS in the DUO crossover study of patients who became relapsed/refractory to ofatumumab in DUO™; Phase I results show defactinib in combination with pembrolizumab and gemcitabine is well tolerated and shows early signs of clinical activity in pancreatic cancer including confirmed partial response and long-term stable disease.

read corporate press release

Kyowa Kirin Presents New Data for Mogamulizumab from Its Lead Program in Cutaneous T-cell Lymphoma (CTCL) at ASCO

(Kyowa Kirin) June 4, 2018 - Quality of life and patient health outcomes data from the pivotal MAVORIC trial is being reported for the first time.

read corporate press release

PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin

(PharmaMar) June 5, 2018 - PharmaMar has presented today how crossover has had an influence on the overall survival of the ADMYRE trial. The impact on overall survival of those patients that relapsed after receiving dexamethasone as a single agent and who were subsequently treated with plitidepsin in combination with dexamethasone was analyzed.

read corporate press release

NewLink Genetics Announces Final Results from Two Phase 2 Studies of Indoximod Presented at ASCO 2018

(Taiwan News) June 4, 2018 - NewLink Genetics Corporation today announced that data from two Phase 2 studies of indoximod, used in combination with other agents, were presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

read article

Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

(Dynavax) June 4, 2018 - Dynavax Technologies Corporation today announced data from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada) in patients with advanced melanoma.

read corporate press release

PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018

(PharmaMar) June 4, 2018 - PharmaMar today announced new data on the recurrent small-cell lung cancer patients cohort of the phase II basket study with lurbinectedin as a single agent, will be presented at the American Society of Clinical Oncology (ASCO) annual meeting, being held from the 1st to the 5th of June in Chicago.

read corporate press release

Blood Mutations Could Contaminate Genetic Analyses Of Tumors

(UNC Lineberger) June 4, 2018 - UNC Lineberger researchers and colleagues led by Catherine C. Coombs, MD, reported research findings at the 2018 American Society of Clinical Oncology Annual Meeting that showed blood cell mutations accounted for as many as 8 percent of the mutations identified in large-scale genetic sequencing efforts at two major academic centers.

read article

Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer

(PipelineReview.com) June 5, 2018 - Additional data from phase 2 investigator-initiated trial of 177Lu-PSMA-617 presented at American Society of Clinical Oncology (ASCO).

read article

ASCO Wrap: Cancer Combos, Precision Meds, Stock Movers & More

(Xconomy National) June 5, 2018 - At ASCO, there were two major themes: the feverish and flawed race to develop cancer immunotherapy combinations, and the progress of “tissue agnostic” cancer drugs, the advanced guard of precision medicine.

read article
Next Page